Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rae Davis

Interventional Pain Medicine Lansdowne, VA Medical Doctor

NPI 1801822630 CMS profile 36003

19500 Sandridge Way, Ste 100, Lansdowne, VA 20176

Open in the dashboard

General payments

$12,446

561 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rae Davis of Lansdowne, VA is reported in the CMS Open Payments database as having received $12,446 across 561 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,851 84
2024 General $1,689 80
2023 General $1,883 74
2022 General $2,001 70
2021 General $1,831 94
2020 General $1,578 72
2019 General $1,613 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rae Davis
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Rae Davis were reported at $1,851. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Rae Davis Interventional Pain Medicine median Middle half National median
2019 $1,613 $684 $216–$2,079 $163
2020 $1,578 $382 $122–$1,109 $114
2021 $1,831 $552 $167–$1,554 $132
2022 $2,001 $605 $187–$1,924 $149
2023 $1,883 $671 $195–$1,915 $160
2024 $1,689 $684 $206–$1,837 $164
2025 $1,851 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,188 49 payments
  2. AbbVie, Inc. $1,057 50 payments
  3. Collegium Pharmaceutical, Inc. $1,015 54 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $764 55 payments
  5. Vertos Medical, Inc. $654 10 payments
  6. IBSA Pharma Inc. $608 40 payments
  7. SI-BONE, Inc. $604 8 payments
  8. Boston Scientific Corporation $536 20 payments
  9. Pfizer Inc. $521 36 payments
  10. Scilex Pharmaceuticals Inc. $489 29 payments
  11. Other $5,010 210 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,412 559 payments
  2. Education $35 2 payments
Products named General payments · program years 2019–2025
  1. XTAMPZA $865 45 payments
  2. RELISTOR Gastroenterology $726 53 payments
  3. RELISTOR Gastroenterology $726 51 payments
  4. QULIPTA $679 27 payments
  5. UBRELVY $676 36 payments
  6. mild Device Kit $654 10 payments
  7. Licart $608 40 payments
  8. Tirosint $531 34 payments
  9. VYEPTI $482 21 payments
  10. NURTEC ODT $363 28 payments
  11. Other $8,998 410 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

477

Median for Interventional Pain Management: 1,220

Drug cost

$13,252

Median for Interventional Pain Management: $39,344

Branded share of claims

31.9%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 19 $4,730
Lidocaine Generic 15 $1,533
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 66 $1,195
Gabapentin Generic 87 $1,134
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 42 $1,108
Tramadol Hcl Er Tramadol Hcl Brand 14 $812
Morphine Sulfate Er Morphine Sulfate Brand 30 $579
Oxycodone Hcl Generic 34 $551
Pregabalin Generic 34 $530
Tramadol Hcl Generic 35 $287

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$387,146

Of which drugs: $7,827

Medicare patients

575

Average age 76

Services billed

7,082

387 women, 188 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 30%
Diabetes 29%
Ischemic heart disease 25%
Osteoporosis 25%
Chronic kidney disease 22%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 11 40 $3,562
Injection, methylprednisolone acetate, 1 mg J1010 Office 48 2,540 $238
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 12 35 $161
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 85 1,930 $147
Injection, ketorolac tromethamine, per 15 mg J1885 Office 14 36 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $270
$270 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $220
$220 — —
VYEPTI
  • Lundbeck LLC $204
$204 — —
NURTEC ODT
  • PFIZER INC. $76
$76 — —
ZAVZPRET
  • PFIZER INC. $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

561 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record